The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Bio-Gene Technology Ltd stock forecast from 0 analysts, the average analyst target price for Bio-Gene Technology Ltd is not available over the next 12 months. Bio-Gene Technology Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bio-Gene Technology Ltd is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Bio-Gene Technology Ltd’s stock price was AUD 0.045. Bio-Gene Technology Ltd’s stock price has changed by +2.27% over the past week, -4.26% over the past month and -51.61% over the last year.
No recent analyst target price found for Bio-Gene Technology Ltd
No recent average analyst rating found for Bio-Gene Technology Ltd
Company Overview Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University to support research and field operations relating to processing and distillation of oil from biomass; AgriFor Scientific, a chemistry product; cesar for assessing the insecticidal activity of molecules against a various insect species; CSIRO, a chemistry development process; Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University, a chemical analysis of natural products; University of Florida; and University of Technology. It serves animal health, crop protection, grain storage, public health, and consumer applications. The company was incorporated in 1995 and is based in Melbourne, Australia. Address: 400 Collins Street, Melbourne, VIC, Australia, 3000 Read Less
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; Qcide, a na...Read More
Frequently Asked Questions About Bio-Gene Technology Ltd (BGT:AU) Stock
Stock Target Advisor's fundamental analysis for Bio-Gene Technology Ltd's stock is Very Bearish.
Unfortunately we do not have enough data on BGT:AU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BGT:AU's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BGT:AU's stock to indicate if its overvalued.
The last closing price of BGT:AU's stock was AUD 0.05.
The most recent market capitalization for BGT:AU is AUD 9.06M.
Unfortunately we do not have enough analyst data on BGT:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bio-Gene Technology Ltd's stock.
As per our most recent records Bio-Gene Technology Ltd has 0 Employees.
Bio-Gene Technology Ltd's registered address is 456 Lonsdale Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Bio-Gene Technology Ltd's website at https://www.bio-gene.com.au.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Bio-Gene Technology Ltd (BGT:AU) Stock
Stock Target Advisor's fundamental analysis for Bio-Gene Technology Ltd's stock is Very Bearish.
Unfortunately we do not have enough data on BGT:AU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BGT:AU's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BGT:AU's stock to indicate if its overvalued.
The last closing price of BGT:AU's stock was AUD 0.05.
The most recent market capitalization for BGT:AU is AUD 9.06M.
Unfortunately we do not have enough analyst data on BGT:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bio-Gene Technology Ltd's stock.
As per our most recent records Bio-Gene Technology Ltd has 0 Employees.
Bio-Gene Technology Ltd's registered address is 456 Lonsdale Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Bio-Gene Technology Ltd's website at https://www.bio-gene.com.au.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BGT:AU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
